Is Cefadroxil Nephrotoxic?
Cefadroxil is not nephrotoxic. Unlike aminoglycosides and certain other cephalosporins, cefadroxil does not cause direct kidney injury, though dose adjustment is required in patients with pre-existing renal impairment.
Evidence from FDA Drug Labeling
The FDA label for cefadroxil 1 explicitly states that the drug "should be used with caution in the presence of markedly impaired renal function" but does not list nephrotoxicity as an adverse effect. The adverse reactions section 1 comprehensively lists gastrointestinal effects, hypersensitivity reactions, hepatic dysfunction, and hematologic abnormalities, but nephrotoxicity is notably absent. The only kidney-related mention is "renal dysfunction" listed among rare adverse reactions reported for the cephalosporin class generally—not specifically attributed to cefadroxil.
Importantly, the label states that "cefadroxil is substantially excreted by the kidney" 1, which explains why dosage adjustment is needed in renal impairment—not because the drug damages kidneys, but because impaired kidneys cannot clear it effectively, leading to drug accumulation.
Contrast with Truly Nephrotoxic Antibiotics
The evidence clearly distinguishes cefadroxil from genuinely nephrotoxic agents:
- Aminoglycosides (gentamicin, tobramycin, amikacin): Cause nephrotoxicity in 3.4-8.7% of patients 2, with streptomycin requiring discontinuation in ~2% 3
- Capreomycin: Causes significant renal toxicity requiring discontinuation in 20-25% of patients 3, 2
- Cefoxitin (a second-generation cephalosporin): Listed with "acute renal failure, toxic nephropathy (rare)" and increased nephrotoxicity risk when combined with aminoglycosides or furosemide 4
Recent Protective Research Findings
Remarkably, recent research 5 demonstrates that cefadroxil may actually protect against nephrotoxicity caused by other drugs. This 2025 study showed that cefadroxil protected mice from colistin-induced kidney damage by targeting the SLC15A2/PEPT2 transporter, which mediates uptake of nephrotoxic drugs into proximal tubular cells. Cefadroxil reduced both cytotoxicity and inflammatory responses in cultured proximal tubular cells exposed to colistin.
Clinical Implications
In patients with normal renal function: Use standard cefadroxil dosing (500 mg every 12 hours for adults 6) without concern for kidney damage.
In patients with pre-existing renal impairment: Dose adjustment is necessary 1 because the drug accumulates due to reduced clearance—not because it will worsen kidney function. Monitor renal function as you would with any renally-cleared medication.
Common pitfall to avoid: Do not confuse the need for dose adjustment in renal impairment with nephrotoxicity. The former reflects pharmacokinetic changes (reduced drug clearance), while the latter would indicate direct kidney injury—which cefadroxil does not cause.
The KDIGO conference 7 framework for classifying nephrotoxic drugs distinguishes between agents causing "kidney dysfunction" (hemodynamic effects) versus "kidney injury" (tubular/structural damage). Cefadroxil falls into neither category—it simply requires renal clearance without damaging kidney tissue.